Edwards Lifesciences (EW) Stock Forecast, Price Target & Predictions
EW Stock Forecast
Edwards Lifesciences stock forecast is as follows: an average price target of $91.70 (represents a 33.93% upside from EW’s last price of $68.47) and a rating consensus of 'Buy', based on 20 wall street analysts offering a 1-year stock forecast.
EW Price Target
The average price target for Edwards Lifesciences (EW) is $91.70 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $140.00 to $66.00. This represents a potential 33.93% upside from EW's last price of $68.47.
EW Analyst Ratings
According to 20 Wall Street analysts, Edwards Lifesciences's rating consensus is 'Buy'. The analyst rating breakdown for EW stock is 0 'Strong Buy' (0.00%), 14 'Buy' (70.00%), 5 'Hold' (25.00%), 1 'Sell' (5.00%), and 0 'Strong Sell' (0.00%).
Edwards Lifesciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | David Rescott | Robert W. Baird | $73.00 | $69.63 | 4.84% | 6.62% |
| Oct 11, 2024 | Patrick Wood | Morgan Stanley | $70.00 | $68.26 | 2.55% | 2.23% |
| Oct 07, 2024 | William Plovanic | Canaccord Genuity | $66.00 | $65.49 | 0.78% | -3.61% |
| Sep 18, 2024 | Matthew Taylor | Jefferies | $70.00 | $67.23 | 4.12% | 2.23% |
| Sep 13, 2024 | Richard Newitter | Truist Financial | $71.00 | $68.13 | 4.21% | 3.70% |
| Sep 09, 2024 | Matt Miksic | Barclays | $80.00 | $66.81 | 19.74% | 16.84% |
| Sep 09, 2024 | Larry Biegelsen | Wells Fargo | $80.00 | $66.81 | 19.74% | 16.84% |
| Jul 31, 2024 | Narumi Nakagiri | Daiwa | $72.00 | $63.64 | 13.14% | 5.16% |
| Jul 30, 2024 | Joanna Wuensch | Citigroup | $83.00 | $63.74 | 30.22% | 21.22% |
| Jul 25, 2024 | Robbie Marcus | J.P. Morgan | $72.00 | $60.58 | 18.85% | 5.16% |
The latest Edwards Lifesciences stock forecast, released on Oct 15, 2024 by David Rescott from Robert W. Baird, set a price target of $73.00, which represents a 4.84% increase from the stock price at the time of the forecast ($69.63), and a 6.62% increase from EW last price ($68.47).
Edwards Lifesciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 15 | 21 |
| Avg Price Target | $69.67 | $76.00 | $84.10 |
| Last Closing Price | $68.47 | $68.47 | $68.47 |
| Upside/Downside | 1.75% | 11.00% | 22.83% |
In the current month, the average price target of Edwards Lifesciences stock is $69.67, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 1.75% increase as opposed to Edwards Lifesciences's last price of $68.47. This month's average price target is down -8.33% compared to last quarter, and down -17.16% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 01, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 18, 2024 | Jefferies | - | Hold | Downgrade |
| Sep 09, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 09, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 22, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 31, 2024 | Daiwa | - | Outperform | Upgrade |
| Jul 25, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Jul 25, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 25, 2024 | RBC Capital | Outperform | Outperform | Hold |
Edwards Lifesciences's last stock rating was published by Wells Fargo on Oct 01, 2024. The company gave EW a "Buy" rating, the same as its previous rate.
Edwards Lifesciences Financial Forecast
Edwards Lifesciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.53B | $1.48B | $1.53B | $1.46B | $1.35B | $1.32B | $1.37B | $1.34B | $1.33B | $1.31B | $1.38B | $1.22B | $1.19B | $1.14B | $925.00M | $1.13B | $1.17B | $1.09B |
| Avg Forecast | $1.93B | $1.88B | $1.92B | $1.87B | $1.53B | $1.48B | $1.51B | $1.45B | $1.39B | $1.57B | $1.65B | $1.57B | $1.50B | $1.48B | $1.51B | $1.39B | $1.33B | $1.33B | $1.40B | $1.31B | $1.35B | $1.32B | $1.28B | $1.16B | $1.18B | $1.08B | $793.92M | $1.08B | $1.14B | $1.04B |
| High Forecast | $1.93B | $1.88B | $1.92B | $1.87B | $1.53B | $1.48B | $1.51B | $1.45B | $1.39B | $1.61B | $1.65B | $1.57B | $1.53B | $1.52B | $1.51B | $1.39B | $1.33B | $1.33B | $1.40B | $1.31B | $1.35B | $1.32B | $1.28B | $1.16B | $1.18B | $1.08B | $793.92M | $1.08B | $1.14B | $1.04B |
| Low Forecast | $1.93B | $1.88B | $1.92B | $1.87B | $1.53B | $1.48B | $1.51B | $1.45B | $1.39B | $1.51B | $1.65B | $1.57B | $1.47B | $1.45B | $1.51B | $1.39B | $1.33B | $1.33B | $1.40B | $1.31B | $1.35B | $1.32B | $1.28B | $1.16B | $1.18B | $1.08B | $793.92M | $1.08B | $1.14B | $1.04B |
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 8 | 7 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.00% | 1.02% | 1.05% | 1.01% | 0.99% | 0.98% | 1.02% | 0.98% | 0.99% | 1.07% | 1.05% | 1.01% | 1.06% | 1.17% | 1.04% | 1.03% | 1.06% |
Edwards Lifesciences's average Quarter revenue forecast for Mar 24 based on 6 analysts is $1.57B, with a low forecast of $1.57B, and a high forecast of $1.57B. EW's average Quarter revenue forecast represents a 2.34% increase compared to the company's last Quarter revenue of $1.53B (Dec 23).
Edwards Lifesciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 8 | 7 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $400.10M | $422.80M | $569.20M | $476.80M | $446.60M | $506.20M | $429.90M | $447.20M | $409.80M | $424.50M | $581.30M | $421.70M | $388.70M | $389.90M | $-143.70M | $389.00M | $367.30M | $322.00M |
| Avg Forecast | $637.88M | $619.41M | $632.93M | $615.78M | $504.34M | $488.33M | $497.08M | $479.76M | $458.67M | $517.45M | $545.30M | $540.37M | $493.68M | $488.15M | $496.46M | $491.25M | $439.89M | $439.96M | $460.49M | $446.59M | $446.24M | $436.03M | $423.10M | $358.89M | $390.68M | $356.38M | $261.86M | $345.78M | $377.63M | $341.86M |
| High Forecast | $637.88M | $619.41M | $632.93M | $615.78M | $504.34M | $488.33M | $497.08M | $479.76M | $458.67M | $530.55M | $545.54M | $648.45M | $503.55M | $500.44M | $496.46M | $589.50M | $439.89M | $439.96M | $460.49M | $535.91M | $446.24M | $436.03M | $423.10M | $430.67M | $390.68M | $356.38M | $261.86M | $414.93M | $377.63M | $341.86M |
| Low Forecast | $637.88M | $619.41M | $632.93M | $615.78M | $504.34M | $488.33M | $497.08M | $479.76M | $458.67M | $497.80M | $545.06M | $432.30M | $483.81M | $478.65M | $496.46M | $393.00M | $439.89M | $439.96M | $460.49M | $357.27M | $446.24M | $436.03M | $423.10M | $287.11M | $390.68M | $356.38M | $261.86M | $276.62M | $377.63M | $341.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.87% | 1.15% | 0.97% | 1.02% | 1.15% | 0.93% | 1.00% | 0.92% | 0.97% | 1.37% | 1.18% | 0.99% | 1.09% | -0.55% | 1.13% | 0.97% | 0.94% |
6 analysts predict EW's average Quarter EBITDA for Mar 24 to be $540.37M, with a high of $648.45M and a low of $432.30M. This is 35.06% upper than Edwards Lifesciences's previous annual EBITDA (Dec 23) of $400.10M.
Edwards Lifesciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 8 | 7 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $369.90M | $384.90M | $307.10M | $340.50M | $398.40M | $343.50M | $406.40M | $373.60M | $335.30M | $340.10M | $489.50M | $338.20M | $309.50M | $325.20M | $-121.90M | $310.60M | $280.20M | $274.70M |
| Avg Forecast | $460.56M | $441.63M | $443.44M | $420.70M | $407.03M | $387.49M | $388.41M | $373.06M | $375.05M | $401.61M | $419.54M | $428.26M | $385.14M | $358.39M | $391.45M | $389.33M | $372.27M | $375.45M | $386.98M | $353.94M | $331.34M | $321.85M | $335.27M | $287.83M | $320.35M | $267.66M | $112.80M | $276.09M | $299.27M | $245.68M |
| High Forecast | $460.56M | $441.63M | $443.44M | $420.70M | $407.03M | $387.49M | $388.41M | $373.06M | $375.05M | $419.59M | $419.61M | $513.92M | $397.18M | $370.53M | $391.45M | $467.20M | $372.27M | $375.45M | $386.98M | $424.72M | $331.34M | $321.85M | $335.27M | $345.40M | $320.35M | $267.66M | $112.80M | $331.31M | $299.27M | $245.68M |
| Low Forecast | $460.56M | $441.63M | $443.44M | $420.70M | $407.03M | $387.49M | $388.41M | $373.06M | $375.05M | $377.63M | $419.46M | $342.61M | $373.11M | $346.24M | $391.45M | $311.46M | $372.27M | $375.45M | $386.98M | $283.15M | $331.34M | $321.85M | $335.27M | $230.26M | $320.35M | $267.66M | $112.80M | $220.87M | $299.27M | $245.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 1.07% | 0.78% | 0.87% | 1.07% | 0.91% | 1.05% | 1.06% | 1.01% | 1.06% | 1.46% | 1.18% | 0.97% | 1.21% | -1.08% | 1.13% | 0.94% | 1.12% |
Edwards Lifesciences's average Quarter net income forecast for Mar 24 is $428.26M, with a range of $342.61M to $513.92M. EW's average Quarter net income forecast represents a 15.78% increase compared to the company's last Quarter net income of $369.90M (Dec 23).
Edwards Lifesciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 8 | 7 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $480.00M | $439.60M | $468.70M | $436.30M | $411.00M | $377.30M | $409.00M | $370.30M | $424.00M | $364.40M | $374.50M | $330.80M | $338.50M | $307.20M | $274.90M | $307.80M | $347.20M | $306.20M |
| Avg Forecast | $559.36M | $543.16M | $555.02M | $539.98M | $442.26M | $428.21M | $435.89M | $420.70M | $402.21M | $453.75M | $478.18M | $424.48M | $432.91M | $428.06M | $435.35M | $385.89M | $385.74M | $385.80M | $403.81M | $350.81M | $391.31M | $382.35M | $371.02M | $281.53M | $342.59M | $312.51M | $229.62M | $273.60M | $331.14M | $299.77M |
| High Forecast | $559.36M | $543.16M | $555.02M | $539.98M | $442.26M | $428.21M | $435.89M | $420.70M | $402.21M | $465.24M | $478.38M | $509.38M | $441.56M | $438.83M | $435.35M | $463.07M | $385.74M | $385.80M | $403.81M | $420.97M | $391.31M | $382.35M | $371.02M | $337.84M | $342.59M | $312.51M | $229.62M | $328.32M | $331.14M | $299.77M |
| Low Forecast | $559.36M | $543.16M | $555.02M | $539.98M | $442.26M | $428.21M | $435.89M | $420.70M | $402.21M | $436.52M | $477.97M | $339.58M | $424.25M | $419.73M | $435.35M | $308.71M | $385.74M | $385.80M | $403.81M | $280.65M | $391.31M | $382.35M | $371.02M | $225.23M | $342.59M | $312.51M | $229.62M | $218.88M | $331.14M | $299.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 1.03% | 1.08% | 1.13% | 1.07% | 0.98% | 1.01% | 1.06% | 1.08% | 0.95% | 1.01% | 1.18% | 0.99% | 0.98% | 1.20% | 1.13% | 1.05% | 1.02% |
Edwards Lifesciences's average Quarter SG&A projection for Mar 24 is $424.48M, based on 6 Wall Street analysts, with a range of $339.58M to $509.38M. The forecast indicates a -11.57% fall compared to EW last annual SG&A of $480.00M (Dec 23).
Edwards Lifesciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 8 | 7 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.61 | $0.63 | $0.51 | $0.56 | $0.65 | $0.55 | $0.65 | $0.60 | $0.54 | $0.55 | $0.79 | $0.54 | $0.50 | $0.52 | $-0.20 | $0.50 | $0.45 | $0.44 |
| Avg Forecast | $0.76 | $0.73 | $0.73 | $0.70 | $0.67 | $0.64 | $0.64 | $0.62 | $0.62 | $0.66 | $0.69 | $0.64 | $0.64 | $0.59 | $0.65 | $0.61 | $0.62 | $0.62 | $0.64 | $0.57 | $0.55 | $0.53 | $0.55 | $0.47 | $0.53 | $0.44 | $0.19 | $0.44 | $0.50 | $0.41 |
| High Forecast | $0.76 | $0.73 | $0.73 | $0.70 | $0.67 | $0.64 | $0.64 | $0.62 | $0.62 | $0.69 | $0.69 | $0.64 | $0.66 | $0.61 | $0.65 | $0.61 | $0.62 | $0.62 | $0.64 | $0.57 | $0.55 | $0.53 | $0.55 | $0.47 | $0.53 | $0.44 | $0.19 | $0.44 | $0.50 | $0.41 |
| Low Forecast | $0.76 | $0.73 | $0.73 | $0.70 | $0.67 | $0.64 | $0.64 | $0.62 | $0.62 | $0.62 | $0.69 | $0.64 | $0.62 | $0.57 | $0.65 | $0.61 | $0.62 | $0.62 | $0.64 | $0.57 | $0.55 | $0.53 | $0.55 | $0.47 | $0.53 | $0.44 | $0.19 | $0.44 | $0.50 | $0.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 1.06% | 0.79% | 0.92% | 1.06% | 0.89% | 1.02% | 1.05% | 0.98% | 1.03% | 1.42% | 1.14% | 0.94% | 1.17% | -1.07% | 1.13% | 0.90% | 1.08% |
According to 6 Wall Street analysts, Edwards Lifesciences's projected average Quarter EPS for Mar 24 is $0.64, with a low estimate of $0.64 and a high estimate of $0.64. This represents a 5.40% increase compared to EW previous annual EPS of $0.61 (Dec 23).
Edwards Lifesciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TNDM | Tandem Diabetes Care | $34.81 | $81.22 | 133.32% | Buy |
| ALGN | Align | $216.02 | $478.50 | 121.51% | Buy |
| EW | Edwards Lifesciences | $68.47 | $91.70 | 33.93% | Buy |
| ZBH | Zimmer Biomet | $104.95 | $133.57 | 27.27% | Hold |
| MDT | Medtronic | $89.79 | $107.91 | 20.18% | Hold |
| PODD | Insulet | $229.13 | $270.93 | 18.24% | Buy |
| DXCM | DexCom | $69.55 | $81.36 | 16.98% | Buy |
| ABT | Abbott Laboratories | $117.89 | $126.45 | 7.26% | Buy |
| SYK | Stryker | $359.73 | $306.09 | -14.91% | Buy |
EW Forecast FAQ
Is Edwards Lifesciences a good buy?
Yes, according to 20 Wall Street analysts, Edwards Lifesciences (EW) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 70.00% of EW's total ratings.
What is EW's price target?
Edwards Lifesciences (EW) average price target is $91.7 with a range of $66 to $140, implying a 33.93% from its last price of $68.47. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Edwards Lifesciences stock go up soon?
According to Wall Street analysts' prediction for EW stock, the company can go up by 33.93% (from the last price of $68.47 to the average price target of $91.7), up by 104.47% based on the highest stock price target, and down by -3.61% based on the lowest stock price target.
Can Edwards Lifesciences stock reach $100?
EW's highest twelve months analyst stock price target of $140 supports the claim that Edwards Lifesciences can reach $100 in the near future.
What is Edwards Lifesciences's current price target trend?
3 Wall Street analysts forecast a $69.67 price target for Edwards Lifesciences (EW) this month, up 1.75% from its last price of $68.47. Compared to the last 3 and 12 months, the average price target increased by 11.00% and increased by 22.83%, respectively.
What are Edwards Lifesciences's analysts' financial forecasts?
Edwards Lifesciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.97B (high $5.97B, low $5.97B), average EBITDA is $1.97B (high $1.97B, low $1.97B), average net income is $1.56B (high $1.56B, low $1.56B), average SG&A $1.73B (high $1.73B, low $1.73B), and average EPS is $2.57 (high $2.57, low $2.57). EW's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $7.6B (high $7.6B, low $7.6B), average EBITDA is $2.51B (high $2.51B, low $2.51B), average net income is $1.77B (high $1.77B, low $1.77B), average SG&A $2.2B (high $2.2B, low $2.2B), and average EPS is $2.92 (high $2.92, low $2.92).
Did the EW's actual financial results beat the analysts' financial forecasts?
Based on Edwards Lifesciences's last annual report (Dec 2023), the company's revenue was $6B, beating the average analysts forecast of $5.88B by 2.18%. Apple's EBITDA was $1.53B, missing the average prediction of $1.97B by -22.11%. The company's net income was $1.4B, missing the average estimation of $1.52B by -8.00%. Apple's SG&A was $1.82B, beating the average forecast of $1.68B by 8.46%. Lastly, the company's EPS was $2.31, missing the average prediction of $2.49 by -7.10%. In terms of the last quarterly report (Dec 2023), Edwards Lifesciences's revenue was $1.53B, beating the average analysts' forecast of $1.5B by 2.49%. The company's EBITDA was $400.1M, missing the average prediction of $493.68M by -18.96%. Edwards Lifesciences's net income was $369.9M, missing the average estimation of $385.14M by -3.96%. The company's SG&A was $480M, beating the average forecast of $432.91M by 10.88%. Lastly, the company's EPS was $0.61, missing the average prediction of $0.637 by -4.29%